Alector ALEC
- Market cap
- $240.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 17.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $13.9M
- −83% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −66.0%
Alector trades at 17.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $13.9M over the last twelve months, down 83% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $9.1M−39% | $15.2M+5% | $15.9M−4% | $15.1M−73% | $15.3M+68% | $54.2M+257% | $3.7M−77% | $7.9M−48% | $3.3M−79% | $6.2M−89% | $1M−72% | $3.3M−58% | |
| R&D | $46.3M−4% | $47.7M−12% | $45.2M−13% | $46.3M+0% | $48M+4% | $46.5M−3% | $33.6M−26% | $27.6M−40% | $29.4M−39% | $32.5M−30% | $17.9M−47% | $19.5M−30% |
| SG&A | $13.4M−6% | $14.9M−3% | $14.4M−2% | $14.4M+6% | $15.8M+18% | $15M+1% | $14.7M+2% | $14.4M+0% | $11.5M−27% | $13.3M−11% | $8.1M−45% | $8.3M−43% |
| −$50.6M+6% | −$47.5M−14% | −$43.7M−13% | −$45.6M+1171% | −$48.4M−4% | −$7.2M−85% | −$44.7M+2% | −$34.1M−25% | −$37.6M−22% | −$39.6M+446% | −$24.9M−44% | −$24.4M−29% | |
| Pre-tax income | −$43.2M−5% | −$39.8M−23% | −$36.1M−20% | −$38.6M | −$42.2M−2% | −$2M−95% | −$40.5M+12% | −$30.5M−21% | −$34.7M−18% | −$37.1M+1731% | −$22.9M−43% | −$22.9M−25% |
| $1.3M+71% | $1.7M+131% | $7K−99% | $73K−95% | $0 | $48K−97% | $0 | $0 | $0 | $168K+250% | $0 | $130K | |
| Net income | −$44.5M−4% | −$41.4M−21% | −$36.1M−21% | −$38.7M | −$42.2M−5% | −$2.1M−95% | −$40.5M+12% | −$30.5M−21% | −$34.7M−18% | −$37.3M+1697% | −$22.9M−43% | −$23M−25% |
| −$0.53−5% | −$0.49−22% | −$0.38−31% | −$0.40 | −$0.43−19% | −$0.02−96% | −$0.41+8% | −$0.30−25% | −$0.34−21% | −$0.34+1600% | −$0.21−49% | −$0.21−30% | |
| 83.9M+2% | 84.4M+2% | 93.8M+13% | 96.7M+16% | 97.5M+16% | 98.3M+17% | 99.4M+6% | 100.4M+4% | 102.6M+5% | 109.5M+11% | 110.6M+11% | 111.2M+11% |
EPS, diluted: 7 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Alector's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALECAlector | $240.1M | n/m | 24.3× | 17.3× | −83% | n/m | |
| PLXProtalix BioTherapeutics | $206.3M | 11.1× | 33.6× | 2.6× | +30% | 23.5% | |
| MGTXMeiraGTx | $895.1M | 13.1× | 15.4× | 2.3× | n/m | 19.9% | |
| VCELVericel | $2.1B | 88.1× | 157× | 6.8× | +23% | 7.9% | |
| Peer median | $895.1M | 13.1× | 33.6× | 2.6× | +27% | 19.9% |
More on Alector
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .